Posted in | Nanobusiness

Ex-President and CEO of Thermo Fibergen to Join Owlstone Nanotech Board

Advance Nanotech, Inc. (OTCBB: AVNA) is pleased to announce that Dr. Yiannis Monovoukas, Ph.D., MBA has agreed to join the board of directors of Owlstone Nanotech, Inc. ("Owlstone"). Dr. Monovoukas is currently Chairman, President and CEO of TEI Biosciences Inc, a privately held regenerative medicine company based in Boston, Massachusetts.

Prior to TEI Biosciences, Dr. Monovoukas was President and CEO of Thermo Fibergen, a spin out from Thermo Electron where Dr. Monovoukas led the company from R&D concept through to becoming a profitable public company. Prior to Thermo Fibergen, Dr. Monovoukas worked at Thermo Electron as a corporate business analyst and at Raychem Corporation as an engineer/scientist. Dr. Monovoukas is currently on the advisory committee for LifeTech Boston, an initiative dedicated to fostering the growth of Boston's life sciences sector.

"We are pleased to have Yiannis join the Owlstone team on its board of directors," commented Bret Bader, CEO of Owlstone. "Yiannis has strong and proven experience in bringing technology products to market, along with a deep understanding of the biomedical markets in which we believe Owlstone's technology is applicable. In addition, Yiannis' prior experience at Thermo Electron provides Owlstone with additional expertise in the detection instruments market."

"Owlstone's technology has transformative potential in a wide variety of markets," remarked Dr. Monovoukas. "I am looking forward to working closely with the Owlstone team on pursuing its product commercialization roadmap along with evaluating additional markets where its technology has relevance."

Dr. Monovoukas holds a bachelor's of science degree from Columbia University and MS and Ph.D. degrees from Stanford University. He also has an MBA from the Harvard Business School. Dr. Monovoukas resides in Weston, Massachusetts.


Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback